top of page

BioRN Lounge 03/2024: The EU´s planned AI legislation- relevance for biotech and pharma



Heidelberg, March 19th:


Prof. Dr. Dr. Tade Spranger, counsel at RITTERSHAUS Rechtsanwälte PartmbB shed light on the most important aspects at yesterday's BioRN Lounge. 


In a nutshell:

  • Complex issues in an increasingly complex regulatory environment

  • Liability risks and the sanctioning of certain regulatory violations are forcing companies, but also researchers, to deal with the legal requirements - as early as possible.

  • There are numerous opportunities, for example with regard to early product customisation, the development of services, the comprehensive use of secondary data available from other stakeholders, or “regulatory cherry picking”


Many questions remain unanswered and BioRN is going to continue the discussion within its network.



Comments


bottom of page